> ## Content Index
> Fetch the complete content index at: https://www.ardmt.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tonnage quantities
- URL: https://www.ardmt.com/tonnage-quantities/
- Published: 2026-07-19T07:33:57.000Z
- Updated: 2026-07-19T07:33:57.000Z
- Description: Eli Lilly's 3.8 billion dollar move into psychedelic medicine is being described as an arrival. Its own history makes it look more like a return, and the drug it is buying carries a contested history of its own
- Author: Stephen Page
- Tags: ARDMT Field Notes, Exploration

*Eli Lilly's 3.8 billion dollar move into psychedelic medicine is being described as an arrival. Its own history makes it look more like a return, and the drug it is buying carries a contested history of its own.*

---

## The acquisition

On 16 July 2026, Eli Lilly agreed to buy AtaiBeckley. The terms are 6.75 dollars a share in cash, valuing the equity at roughly 2.8 billion dollars, with contingent value rights worth up to another 2.50 dollars a share tied to future milestones, which would bring the total to about 3.8 billion. The cash offer is around a 40 per cent premium to the recent trading price, the deal is expected to close in the third quarter of 2026, and about 15 per cent of the shares are already locked in by voting agreements. Almost every account has led with that headline number, and it is a large one.

The number is the least revealing part of the announcement. Three things sit underneath it that the coverage has mostly skated past: who is doing the buying and what that buyer once did with psychedelics, who actually collects the money, and what the drug at the centre of the deal really is, both as a clinical asset and as a substance with a history of its own.

The money is quickly told. The largest single beneficiary is Christian Angermayer, the German investor who founded atai Life Sciences and is now AtaiBeckley's chairman and largest shareholder. Peter Thiel, an early and major backer of atai, is among the others, along with Angermayer's own Apeiron Investment Group and a set of healthcare-focused institutions. The billions flow substantially to the tech-finance investor class that bet on this sector early, and Angermayer has said as much in spirit, calling the deal the best path forward for patients and shareholders and noting that when he began contemplating psychedelic medicine in 2014 it looked like a crazy idea, whereas today it feels almost inevitable. That is a fair description of a successful venture bet. It is worth holding onto precisely because it is not the description the field usually reaches for, which is one of healing and vindication. Both are true at once, and the second tends to obscure the first.

Now the part the headlines skipped entirely.

## The buyer's older business

The origin of LSD is a story most readers here already know. Albert Hofmann first synthesised the compound at the Swiss firm Sandoz in 1938, and in 1943 he discovered, on himself, what it did. Sandoz is the laboratory behind LSD in the sense that matters most, and it is now part of Novartis. That is not the company buying AtaiBeckley. But a decade after Hofmann, on the other side of the Atlantic, a second company entered the story, and it is the one signing the cheque this month.

By the early 1950s American intelligence had become intensely interested in LSD as a possible instrument of interrogation and behavioural control, and it did not want to depend on a foreign supplier. Sandoz held the patent and made the drug from ergot, a fungus that grows on rye, which meant the raw material was scarce and the supply chain ran through Switzerland. So the CIA, under the MKUltra programme and as the sixth of its numbered subprojects, paid an American pharmaceutical company to develop a reliable domestic source of LSD, made by a route that did not depend on the fungus at all. In 1954 that company succeeded. Its chemist Edmund Kornfeld, working with the Harvard laureate R. B. Woodward as a consultant, achieved the first total synthesis of lysergic acid, the core of the LSD molecule, in a fifteen-step laboratory route. It was a genuine landmark in synthetic chemistry, and it freed the manufacture of LSD from the ergot bottleneck for the first time.

The company was Eli Lilly.

Precision matters here, because this is the claim most likely to be attacked, and it survives attack only if it is stated exactly. Lilly did not discover LSD, and it did not run the human experiments. What it did was solve the manufacturing problem, and having solved it, agree to supply the drug to the Agency. The National Security Archive, which in 2024 released a large scholarly collection of MKUltra documents, describes Lilly as having developed the capacity to produce LSD in "tonnage quantities." That phrase is arresting and it is also easy to misread. LSD is active in doses measured in millionths of a gram, so a literal tonne of it would represent an almost unimaginable number of active doses. What the phrase appears to describe is scalable manufacturing capacity, freed from the ergot constraint, rather than a literal stockpile of finished drug. That capacity is the point. It gave the CIA, in the Archive's account, LSD in abundance, and that expanding domestic supply underwrote the programme of covert dosing that ran through the rest of the decade. Its most notorious victim, the Army scientist Frank Olson, secretly given LSD and dead soon after from a fall from a New York hotel window, belongs to the same programme but to an earlier moment, late 1953, before Lilly's synthesis existed, so his dose was not Lilly's to answer for. The historian Stephen Kinzer, whose account is the standard one, puts the later relationship plainly: the CIA became Lilly's main customer for the drug.

A fair objection arrives here, and the piece is stronger for meeting it. No executive who authorised Lilly's purchase of AtaiBeckley had anything to do with MKUltra. The people are gone and the corporate culture has turned over many times, and a company that shares a name and a legal identity with its 1954 self is not the same moral entity. Corporate continuity is not personal guilt. But companies trade constantly on their long histories when those histories flatter them, and Lilly is no exception, reaching back to insulin and the polio vaccine and a founder who built the firm on scientific integrity. A history invoked when it is useful does not become irrelevant when it is not. The uncomfortable chapter belongs to the same ledger as the proud ones.

## Amanda Feilding and the Beckley lineage

The seller's story carries the human weight of the deal, and it needs one distinction held firmly, because the headlines blur it.

AtaiBeckley is a recent fusion of two companies with almost opposite characters. One, atai Life Sciences, is Angermayer's Berlin-founded, Thiel-backed, Nasdaq-listed psychedelics platform. The other carries one of the most storied names in the field, and to understand what is being sold you have to understand the woman behind it.

Amanda Feilding was born in 1943 at Beckley Park, a sixteenth-century moated hunting lodge in Oxfordshire, and she died there in May 2025, aged eighty-two. She has been called, with justification, the hidden hand behind the modern psychedelic renaissance, and she was also one of its most improbable figures. In December 1970, persuaded that a hole in the skull could expand consciousness, she drilled one into her own forehead with a dental drill and filmed it, keeping a spare drill to hand in case the first jammed, which it did. The act earned her decades of nicknames, from the crackpot countess to the queen of consciousness. She married an earl and became Countess of Wemyss and March, which is why the press calls her the psychedelic countess.

The eccentricity travels; the substance is what matters. In 1998 she built the Beckley Foundation into the coordinating engine of the field's scientific rehabilitation. Its collaboration with Imperial College London, with David Nutt and Robin Carhart-Harris, produced the first modern brain-imaging studies of LSD and the first contemporary trial of psilocybin for depression. She co-authored more than fifty peer-reviewed papers when the word psychedelic could still end a career. If the current legitimacy of this science has a single architect, it is plausibly her.

Here is the distinction to hold. The Beckley Foundation, the non-profit that is her research and policy legacy, is a separate entity, and it was not sold to anyone. What Lilly is buying is Beckley Psytech, the for-profit drug-development company she co-founded in 2019 with her son, Cosmo Feilding Mellen. And this forecloses the sentimental reading before it can start. Feilding did not merely permit the commercial vehicle, she built it, deliberately, on the logic that a body of academic proof-of-concept evidence could only reach patients if it was pushed through the machinery of drug development, which requires capital and regulatory expertise no non-profit possesses. The sale to Lilly is, on that view, the far end of a road she chose to walk, not a betrayal of a legacy she wanted preserved in amber. Her actual legacy, the Foundation, remains what it was.

## The eleven days

The sequence is where a certain unease sets in, and it does not fully lift even when the sentimental version is ruled out.

atai had held a stake in Beckley Psytech since 2021\. Amanda Feilding died on 22 May 2025\. Eleven days later, on 2 June, atai and Beckley announced a definitive agreement to merge, conditioned on a Phase 2b result that duly arrived a month afterwards. The merger completed in November 2025, and in the combined company control passed decisively to the atai side: Angermayer as chairman and largest shareholder, atai's Srinivas Rao as chief executive, and Cosmo Feilding Mellen with a single seat on the board rather than the helm. Eight months later the whole thing was sold to Lilly.

Two things should be said about that, in tension with each other. The first is that the dates alone tell a story that needs no embellishment: the woman who did more than almost anyone to make this science respectable died, and within a fortnight the company bearing her family's name was set on the path that ended at the maker of Prozac, with control of it leaving her family within six months. The second is a caution against reading too much into the timing. A merger of that scale is negotiated over many months, so the eleven-day gap is far more likely a matter of when a finished deal was disclosed than of a sale rushed through once she was gone. The record shows structure and dates, not motive.

Cosmo Feilding Mellen deserves his strongest case, not a caricature. His argument, made consistently, is that the science does no good sitting in academic papers, that turning early evidence into an approved medicine demands resources and regulatory competence only a large company can supply, and that Lilly's scale can advance these treatments faster than a small biotech could alone. That is a serious argument and it may well be correct. The tension is not that he is wrong, it is what the argument costs: responsibility for carrying the drug to approval now rests not with the family or the Foundation but with a pharmaceutical corporation in Indianapolis, and the value built over decades has moved with it. That is not a scandal. It is what the translation of scientific idealism into medicine looks like when it succeeds, and it is worth seeing clearly rather than sentimentally.

## What Lilly is actually buying

Set the ownership story aside, though, and there is still the matter of what, clinically, Lilly has paid for. On its own terms the asset is real, and more mixed than either the deal coverage or its critics allow.

BPL-003 is a synthetic form of 5-MeO-DMT, one of the fastest and most physically overwhelming of the classic psychedelics, formulated as a benzoate salt and delivered as a nasal spray for treatment-resistant depression. Its selling point is brevity. The acute experience is short enough that most patients are ready to leave the clinic in around ninety minutes, against the two hours of monitoring required for the esketamine nasal spray Spravato. Spravato is one of the very small number of drug products carrying a specific FDA indication for treatment-resistant depression; another is Lilly's own Symbyax, a fluoxetine combination, which is to say the company already owns a piece of this category and built it on the same molecule that made Prozac. That ninety-minute window is not a clinical nicety, it is the commercial thesis: it lets BPL-003 slot into the clinic and billing infrastructure already built around Spravato. Lilly is buying a drug shaped to fit an existing system.

The efficacy data are real and should be reported without the promotional gloss. The pivotal Phase 2b study, whose positive result in mid-2025 triggered the atai and Beckley merger, enrolled 193 patients with treatment-resistant depression across roughly forty sites in six countries, ran for eight weeks, and compared two active doses against a low 0.3 milligram comparator, with symptoms scored by centralised, blinded raters. On the primary endpoint, the twelve milligram dose produced a mean reduction of 11.1 points on the standard depression scale at day 29, against 5.8 points for the comparator, a statistically significant difference; the eight milligram dose did slightly better and is the one heading into Phase 3\. Effects appeared within a day or two and held to week eight.

Three caveats belong alongside those numbers, and the announcements omit all three. The first is the comparator, which was not an inert placebo but a low, arguably sub-perceptual dose. At eight to twelve milligrams the 5-MeO-DMT experience is intense and unmistakable, with most participants in the dose-ranging work reporting a full mystical-type experience, so patients almost certainly know which arm they are in even if the remote raters do not. The centralised blinded raters are a real and creditable mitigation against biased scoring, but they cannot touch the expectancy that operates through the patient, and the comparator arm itself improved by 5.8 points, a large placebo response, leaving a drug-versus-comparator gap of a little over five points that is genuine but modest. The second caveat concerns the eye-catching figures that circulate in the press, the remission rates near half and response rates above one in two: those come not from the controlled Phase 2b but from an earlier open-label study of roughly a dozen patients with no control group at all. The third is simply that Phase 3 has not read out, and will not until around 2029.

It is worth being exact about the therapy that surrounds the dose, because the commercial argument turns on it. In Beckley's trials the drug was given with what the company calls standardised psychological support: a trained "psychedelic monitor" met the patient for preparation beforehand, stayed present through the session, and conducted integration sessions afterwards, and the support was explicitly nondirective. This is a deliberately lighter model than the intensive, manualised psychotherapy that accompanied MDMA in its trials, and the lightness is a feature, not an oversight, because it is what makes the treatment scalable. Which sets up the real question. The short duration and the light-touch support are prized in large part because they are convenient: more patients through a clinic, less clinician time, a naturally short psychedelic formulated to sit inside the economics of interventional psychiatry. The prolonged, disruptive character of the experience was, for most of the last century, understood to be the therapeutic point. If the industry now selects for the shortest tolerable version of it, wrapped in the lightest tolerable support, the honest question is whether the altered state is being preserved, medically domesticated, or quietly designed down into an inconvenient cost to be minimised.

Then there is the question of what is ownable, because it explains the whole structure of the deal. You cannot patent 5-MeO-DMT. It is a naturally occurring molecule, described in the literature for more than half a century, and no one owns it. So the value sits in everything wrapped around it: the specific benzoate salt, on which Beckley holds granted composition-of-matter patents in the United States, United Kingdom and Europe, the intranasal formulation, the method of use, and the delivery device, a spray already approved in another product. This is how pharmaceutical value is now built around old or natural molecules, and it reframes the deal. Lilly is not buying a discovery. It is buying a patent estate, a regulatory position, a completed dataset and a market lead, assembled around a compound anyone is free to make, which is exactly why a direct rival, the Dublin-listed GH Research, is racing the same molecule to market by an inhaled route. The race is over the wrapper, not the compound.

## The molecule's own history

There is one more layer, and it is the one closest to this publication's usual concerns. Where does 5-MeO-DMT come from, before a laboratory makes it?

In nature it is produced by the only vertebrate currently known to make it, the Sonoran Desert toad, in the secretions of its glands, where the compound was identified in the mid-1960s. The story often attached to it, of ancient Indigenous ceremony, is far more recent than its mystique implies. The practice of smoking dried toad secretion traces to a self-published pamphlet from 1984, and a 2026 paper in the journal Psychedelics, pointedly titled "Fabricated Ancestrality," argues that the framing of "ancestral toad medicine" is a recent construction dressed up as antiquity to lend the practice cultural authority. The precise point matters: plant-derived 5-MeO-DMT, in the yopo snuffs of the Amazon and Caribbean, does have a long documented Indigenous history. The toad practice, specifically, does not. This should sound familiar to anyone who has followed our position on ayahuasca. A commercially convenient origin myth, retrofitted onto a substance to lend it the authority of the immemorial, is not the same thing as a documented practice, and does not become one through repetition in retreat brochures.

The consequences are not abstract. A wellness and tourism boom, amplified by celebrity endorsement, has driven the harvesting and milking of wild toads at a scale that has alarmed conservationists and drawn legal restrictions across the animal's US range, where it is listed as endangered in California and threatened in New Mexico and its collection is regulated in Arizona. Conservationists now urge users to leave the toads alone and switch to synthetic material, which is molecularly identical and free from any direct pressure on wild populations. On the conservation question the pharmaceutical version offers a clear advantage: a precisely dosed synthetic takes the pressure off a threatened animal entirely. But the provenance question does not disappear because the toad is spared. Contemporary Sonoran peoples, among them Comcaac, Tohono O'odham and Yaqui communities, have in recent decades incorporated the substance into their own practices, and some of their voices argue that the breezy instruction to simply use synthetic can erase living tradition and sidestep any question of reciprocity to the region where the surge began. So the compound Lilly is acquiring, in its synthetic and patented form, carries unresolved questions of provenance and benefit-sharing of the kind the Nagoya framework was designed to make visible, even if its formal application to a long-known, laboratory-made molecule is far from straightforward. The synthetic answers the conservation problem. It leaves the provenance one untouched.

## Prozac, and why pharma stayed away until now

There is an irony in Lilly specifically making this purchase, but it is subtler than the obvious version, and the obvious version is worth correcting.

Lilly was founded in Indianapolis in 1876 by Colonel Eli Lilly, a Civil War veteran and pharmaceutical chemist, in reaction against the quack cure-alls of his day, on a promise to make standardised medicines dispensed on a physician's advice. It went on to commercialise the first insulin, to mass-produce the polio vaccine, and in 1986 to launch Prozac, the drug that installed the daily-pill, chemical-imbalance model of depression in the public mind more firmly than any other. The tempting line is that Lilly is now buying the opposite of Prozac, a drug taken once or twice a year rather than daily, and thereby repudiating its own defining model.

That line is too clean in both directions. The chemical-imbalance story was always a marketing simplification of what SSRIs actually do, and the claim that BPL-003 rewires the brain is likewise a simplification of a mechanism that is far from settled. The sharper point is about business models, not neurochemistry. For decades Big Pharma avoided psychedelics for two structural reasons, laid out clearly by Michael Pollan among others: the molecules offered almost no intellectual property, since compounds like psilocybin are natural and the LSD patents expired long ago, and the industry's economics favour chronic conditions treated by drugs taken every day, not a dose given once. What changed is not that Lilly had a change of heart about maintenance psychiatry. What changed is that both obstacles were engineered away. The patent problem is solved by owning the salt, the formulation and the device rather than the molecule. The revenue problem is solved by the specialist-clinic model, in which an infrequent dose becomes a billable, monitored, reimbursable procedure. Seen this way, Lilly is not abandoning pharmaceutical psychiatry. It is expanding the borders of what pharmaceutical psychiatry can contain, absorbing the critique of the daily pill into a new model it can own. That is a striking departure from the approach the company became synonymous with. It is not a repudiation of it.

## The wider consolidation

None of this is happening alone. In 2025 AbbVie paid up to about 1.2 billion dollars for Gilgamesh's psychedelic compound, the first time a traditional pharmaceutical giant bought an investigational psychedelic outright. Otsuka moved on the methylone developer Transcend for a comparable sum. Johnson and Johnson was already inside the field with Spravato. The AtaiBeckley deal is simply the largest of the sequence so far, part of an unusually intense run of acquisitions and licensing deals by a Lilly flush with revenue from its metabolic-drug portfolio. A fringe science has become an asset class, and the assets are being gathered up by a small number of very large buyers.

## What has changed, and what has not

It would be dishonest to let the historical parallel run as if nothing separates 1954 from 2026\. Almost everything does. Then, LSD was administered covertly, often to people who had not consented and were not told, in the service of behavioural control, funded by an intelligence agency, and hidden. Now a psychedelic is given with informed consent, under clinical protocols and regulatory oversight, to treat a recognised illness, and the ownership is a matter of public patents and press releases. The difference between a person secretly dosed in a safehouse and a patient choosing a monitored treatment for depression is the entire moral distance the field has travelled, and it is real.

And yet the continuities are what make the story worth telling rather than merely recounting. In both eras a small number of powerful institutions control access to these compounds and decide which uses of them are legitimate. In both, the altered state is put to an external purpose defined by those institutions, whether state security then or shareholder return now. In both, knowledge and supply are concentrated rather than shared. What changes at each handover is the stated purpose and the accountability regime. What does not change is that someone powerful decides who may have it, on what terms, and to what end.

## Not a beginning, but a return

Three stories are braided together in this announcement. The first is institutional return. Lilly is not entering psychedelic medicine without a history; it is returning to a field in which it once solved a manufacturing problem for the CIA.

The second is commercial inheritance. The scientific legitimacy Amanda Feilding spent decades building, largely through a non-profit, helped produce a commercial asset now being realised principally for investors. This is not theft. It is how scientific idealism is translated into proprietary medicine when it succeeds, and it deserves to be watched with clear eyes.

The third is the transformation of psychedelics as a class. LSD and 5-MeO-DMT have different biographies, but together their histories pass through worlds that treated altered states, by turns, as weapons, contraband, spiritual technologies, research tools and medicines. Those histories now converge within an apparatus of synthetic manufacture, patents, regulatory control and institutional ownership.

The industry will read this deal as a beginning, the moment Big Pharma finally believed. That reading is not wrong so much as incomplete, because it mistakes a return for a first arrival. The buyer’s own filing cabinet shows that this field has been inside the pharmaceutical industry before. The history of the field shows what had to change before it could come back.

---

*Sources and notes for fact-lock:*

*Deal terms, beneficiaries and CVR structure: Lilly and AtaiBeckley releases of 16 July 2026, plus Bloomberg, FierceBiotech, BioPharma Dive and StockTitan. The DEA-rescheduling CVR milestone is stated in Lilly's own release; Angermayer confirmed as founder, chairman and largest shareholder.*

*Lilly and the CIA: the total synthesis of lysergic acid by Kornfeld et al., J. Am. Chem. Soc. 1954, 76, 5256, is a primary chemistry source. MKUltra Subproject 6 is identified as the Eli Lilly domestic-LSD-source project in the declassified subproject list (MORI ID 17459) and in Stephen Kinzer's* Poisoner in Chief *(2019), which is also the source for the "main customer" characterisation; the "tonnage quantities" phrase is the National Security Archive's (December 2024) and describes capacity. Frank Olson was dosed in November 1953 and died 28 November 1953, before Lilly's synthesis; he is deliberately kept separate from the Lilly supply claim.*

*BPL-003 data: atai/Beckley Phase 2b topline release, 1 July 2025 (193 patients; \~40 sites, 6 countries; quadruple-masked with centralised blinded raters; 0.3 mg comparator; 12 mg primary endpoint 11.1 vs 5.8 MADRS points at day 29; 8 mg advanced), and the Phase 2a open-label proof-of-concept study (\~12 patients, uncontrolled) for the higher remission/response figures. Psychological support (standardised, nondirective, trained "psychedelic monitor," preparation/session/integration) from the Phase 2a paper and trial-registry materials. Patents: granted US/UK/EU composition-of-matter on the benzoate salt; GH Research rivalry per trade coverage. Symbyax (olanzapine/fluoxetine), a Lilly product, FDA-approved for TRD in 2009.*

*5-MeO-DMT provenance: Ortiz Bernal AM, Raison CL, Vargas Prieto AM, Davis AK, "Fabricated ancestrality: The Sonoran Desert toad, psychedelic globalization, and the ecological politics of 5-MeO-DMT," Psychedelics 2026;3:100012\. Also Villa et al., Journal of Psychedelic Studies (2023) and Frontiers in Conservation Science (2025) on conservation; the 1984 Albert Most / Ken Nelson pamphlet (Venom Press) as the origin of the toad-smoking practice; yopo (Anadenanthera) snuff as the documented older Indigenous route to 5-MeO-DMT. Toad legal status: endangered in California, threatened in New Mexico, collection regulated in Arizona; globally IUCN Least Concern, so avoid implying a global threatened listing. "The only vertebrate currently known" and "free from any direct pressure on wild populations" are deliberate hedges.*

*Feilding biography and death (22 May 2025, Beckley Park): Telegraph and New York Times obituaries and the Beckley Foundation notice. Cosmo Feilding Mellen's rationale from the Sifted interview. Merger sequence (agreement 2 June 2025; completion 4–5 November 2025) from atai/AtaiBeckley releases and SEC filings.*